Abstract
Introduction: It is said that molecular target agents are more durable than cytotoxicic ones, although they have their own specific side effects. We experienced a case of non-small cell lung cancer with leptomeningeal metastasis and she had molecular target agents, she had palliation of symptom and prolongation of survival time. Case: Patient is 76 years old Japanese woman without smoking history. In April 2010 speech and gate disturbance was appeared on her, she was examined by CT and MRI, these revealed lung cancer, intrapulmonary metastasis, lymph nodal involvement, leptomeningeal metastasis, brain metastasis, and spinal bone metastasis in vertebras (T1bN1M1b, Stage IV). Symptoms such as gate disturbance, decrease of oral intake, drowsiness was regression rapidly, so patient and family decided discharge to go to home. She started to take elrotinib 100 mg on yth May. at home. She took elrotinib 150 mg since 6th June 2010 until July 2011 on her death. 2 weeks after administration of elrotinib she came to be able to eat and get up. On 6th August 2010 after administration of elrotinib primary lesion of lung cancer showed PR by CT, leptomeningeal and brain metastases showed SD by MRI. Grade 2 of skin rashu was manageable with topical corticosteroids. The remaining days from a diagnosis of the metastasis to lung cancer with leptomeningeal metastasis are reported with around three months. A symptom was relieved by the dosage of erlotinib,and there was not a serious side effect, and the patient could survive for one year and 5 months.
